Медицинские вопросы и проблемы подростков, больных муковисцидозом

Sawyer SM, Afifi RA, Bearinger LH et al. Adolescence: a foundation of future health. Lancet 2012;379:1630-40

Miauton L, Narring F, Michaud PA. Chronic illness, lifestyle and emotional health in adolescence: results of a cross-sectional survey on the health of 15-20-year-olds in Switzerland. Eur J Pediatrics 2003;162:682-9

Sawyer SM, Drew S, Yeo M, Britto M. Adolescents with a chronic condition: challenges living, challenges treating. Lancet 2007;369:1481-9

Sawyer SM, Afifi RA, Bearinger LH et al. Adolescence: a foundation of future health. Lancet 2012;379:1630-40

Sawyer SM, Afifi RA, Bearinger LH et al. Adolescence: a foundation of future health. Lancet 2012;379:1630-40

Patton GC, Coffey C, Sawyer SM et al. Global patterns of mortality in young people: a systematic analysis of population health data. Lancet 2009;374:881-92

Gore FM, Bloem PJN, Patton GC et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet 2011;377:2093-102

Viner RM, Coffey C, Mather С et al. 50-year mortality trends in children and young people: a study of 50 low-income, middle-income, and high-income countries. Lancet 2011;377:1162-74

Sawyer SM, Afifi RA, Bearinger LH et al. Adolescence: a foundation of future health. Lancet 2012;379:1630-40

Patton GC, Viner R. Pubertal transitions in health. Lancet 2007; 369:1130-9

Giedd JN, Blumenthal J, Jeffries NO et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999;2:861-3

Blakemore S-J, Burnett S, Dahl RE. The role of puberty in the developing adolescent brain. Hum Brain Mapp 2010;31:926-33

Blakemore S-J, Burnett S, Dahl RE. The role of puberty in the developing adolescent brain. Hum Brain Mapp 2010;31:926-33

Casey BJ, Getz S, Galvan A. The adolescent brain. Dev Rev 2008; 28:62-77

Steinberg L. A social neuroscience perspective on adolescent risk taking. Dev Rev 2008;28:78-106

Steinberg L. A social neuroscience perspective on adolescent risk taking. Dev Rev 2008;28:78-106

Martin CA, Kelly TH, Rayens MK et al. Sensation seeking, puberty, and nicotine, alcohol, and marijuana use in adolescence. J Am Acad Child Adolesc Psychiatry 2002;41:1495-502

Sawyer SM, Afifi RA, Bearinger LH et al. Adolescence: a foundation of future health. Lancet 2012;379:1630-40

Kessler RC, Berglund P, Dernier O, Jin R, Merikangas KR. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry 2005;62:593-602

Rutter M. Pathways from childhood to adult life. J Child Psychol Psychiatry 1989;30:23-51

Catalano RF, Fagan AA, Gavin LE et al. Adolescent health: application of the prevention science research base. Lancet 2012;379:1653-64

Patton GC, Bond L, Carlin JB et al. Promoting social inclusion in schools: a group-randomized trial of effects on student health risk behavior and well-being. Am J Pub Health 2006;96:1582-7

Litt DM, Stock ML. Adolescent alcohol-related risk cognitions: the roles of social norms and social networking sites. Psychol Addict Behav 2011;25:708-13

McPherson M, Arango P Fox H. A new definition of children with special health care needs. Pediatrics 1998;102:137-10

Bethell CD, Read D, Stein RE, Blumberg SJ, Wells N, Newacheck PW. Identifying children with special health care needs: development and evaluation of a short screening tool. Ambul Pediatr 2002;2:38-48

Sawyer SM, Drew S, Yeo M, Britto M. Adolescents with a chronic condition: challenges living, challenges treating. Lancet 2007;369:1481-9

Sawyer SM, Drew S, Yeo M, Britto M. Adolescents with a chronic condition: challenges living, challenges treating. Lancet 2007;369:1481-9

Sawyer SM, Drew S, Yeo M, Britto M. Adolescents with a chronic condition: challenges living, challenges treating. Lancet 2007;369:1481-9

McPherson M, Arango P Fox H. A new definition of children with special health care needs. Pediatrics 1998;102:137-10

Bethell CD, Read D, Stein RE, Blumberg SJ, Wells N, Newacheck PW. Identifying children with special health care needs: development and evaluation of a short screening tool. Ambul Pediatr 2002;2:38-48

Olsson CA, Boyce M, Toumbourou JW, Sawyer SM. The role of peer support in facilitating psychosocial adjustment to chronic illness in adolescence. Clin Child Psychol Psychiatry 2005;10:78-87

Suris J-C, Michaud P-A, Akre C, Sawyer SM. Health risk behaviours in adolescents with chronic conditions. Pediatrics 2008;122: e1113-18

Sawyer SM, Drew S, Duncan R. Adolescents with chronic disease: the double whammy. Aust Fam Physician 2007;36:2-6

Sanci LA, Sawyer SM, Kang M, Haller-Hester D, Patton GC. Confidential health care for adolescents: reconciling clinical evidence with family values. Med J Aust 2005;183:410-14

Duncan RE, Vandeleur M, Derks A, Sawyer S. Confidentiality with adolescents: what do parents think? J Adolesc Health 2011 ;49:428-30

World Health Organization. Adolescent friendly health services an agenda for change. Geneva: World Health Organization, 2002

Cystic Fibrosis Foundation Patient Registry: 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011

Morgan WJ, Butler SM, Johnson CA et al. Epidemiologic Study of Cystic Fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28:231-41

Cystic Fibrosis Foundation Patient Registry: 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011

Cystic Fibrosis Foundation Patient Registry: 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011

Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9

Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91

Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009;8S:S15-S19

Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91

Bonnel AS, Song SM, Kesavarju К et al. Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatr Pulmonol 2004; 38:396-105

Sly PD, Brennan S, Gangell С et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180:146-52

Stick SM, Brennan S, Murray С et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155:623-8

Pillarisetti N, Linnane B, Ranganathan S; AREST CF. Early bronchiectasis in cystic fibrosis detected by surveillance CT. Respirology 2010; 15:1009-11

Farrell PM, Li Z, Kosorok MR et al. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003; 36:230-40

Gustafsson PM, Aurora P Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003; 22:972-9

Kraemer R, Blum A, Schibler A, Ammann RA, Gallati S. Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 171:371-8

Kieninger E, Singer F, Fuchs О et al. Long-term course of lung clearance index between infancy and school-age in cystic fibrosis subjects. J Cyst Fibros 2011; 10:487-90

Rosenthal M. How good are pulmonary function tests as an indicator of short and long term health status? Pediatr Pulmonol 2009; S32:171-2

Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009;8S:S15-S19

Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med 2006; 174:7 80-6

Rabin HR, Butler SM, Wohl ME et al. Epidemiologic study of cystic fibrosis. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37:400-6

Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141:914-21

Smith AL, Fiel S, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123:1495-502

BlumerJL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128:2336-16

Sanders DB, Hoffman LR, Emerson J et al. Return of FEV(1) after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-34

Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ Jr. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010; 182:1137-13

VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010; 11:137

Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637-12

Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30

Saiman L, Marshall ВС, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56

Jaques A, Daviskas E, Turton JA et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133:1388-96

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. EMEA/ CHMP/EWP/9147/2008, October, 2009. Available at: http://www.emea.europa.eu/pdfs/human/ewp/914708en.pdf. Accessed 18 September 2012

Ramsey BW, Davies J, McElvaney NG et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72

Rosenfeld M, Pepe MS, Longton G, Emerson J, FitzSimmons S, Morgan

Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15:75-88

Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-87

Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14

Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9

Konstan MW, Wagener JS, Yegin A, Millar SJ, Pasta DJ, VanDevanter DR. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. J Cyst Fibros 2010; 9:332-8

VanDevanter DR, Wagener JS, Pasta DJ et al. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol 2010;45:1156-66

Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9

Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009;8S:S15-S19

Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med 2006; 174:7 80-6

Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med 2006; 174:7 80-6

Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros 2009;8S:S15-S19

Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9

Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9

Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995; 48:1041-9

Kristidis P Bozon D, Corey M et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992;50:1178-84

The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. New Engl J Med 1993; 329:1308-13

McKone EF, Emerson SS, Edwards KL et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361:1671-6

McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006; 130:1441-7

Sanders DB, Hoffman LR, Emerson J et al. Return of FEV(1) after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-34

Wagener JS, VanDevanter DR, Pasta DJ, Regelmann W, Morgan WJ, Konstan MW. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2012. (In press) DOI: 10.1002/ ppul. 22652

Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9

Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54

Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72

Dziuban EJ, Saab-Abazeed L, Chaudhry SR, Streetman DS, Nasr SZ. Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol 2010; 45:450-8

Modi AC, Marciel KK, Slater SK, Drotar D, Quittner AQ. The influence of parental supervision on medical adherence in adolescents with cystic fibrosis: developmental shifts from pre to late adolescence. Children's Health Care 2008; 37:78-92

Vandenbranden SL, McMullen A, Schechter MS et al. Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatr Pulmonol 2012;47:135-43

Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-54

Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151:249-54

Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007;176:1084-9

Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ. The initiation of inhaled corticosteroid therapy in cystic fibrosis patients is associated with a slower rate of lung function decline. J Pediatr 2008; 153:746-51

Konstan MW, Wagener JS, Pasta DJ et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011;46:545-53

Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54

Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72

Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72

Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54

Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012; 129:348-55

Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127:725-34

Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15:75-88

Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-87

Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012; 129:348-55

VanDevanter DR, Rasouliyan LH, Murphy TM et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43:739-44

Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72

VanDevanter DR, Rasouliyan LH, Murphy TM et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43:739-44

Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 1999;28:248-54

Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72

Cystic Fibrosis Foundation Patient Registry: 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011

Cystic Fibrosis Foundation Patient Registry: 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011

Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. J Cyst Fibros2009;8S:S15-S19

Konstan MW, Morgan WJ, Butler SM et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134-9

Konstan MW, VanDevanter DR, Rasouliyan L et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-72

Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16

Schumacher KL, Meleis Al. Transition: a central concept in nursing. Image J NursSch 1994;26:119-27

Schumacher KL, Meleis Al. Transition: a central concept in nursing. Image J NursSch 1994;26:119-27

] Kralik D, Visentin K, van Loon A. Transition: a literature review. J Adv Nurs 2006; 55:320-9

World Health Organization. Child and adolescent health. Available at: http://www.searo.who.int/en/Section13/Section1245_4980.htm Accessed 19 September 2012

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16

Brumfield K, Lansbury G. Experiences of adolescents with cystic fibrosis during their transition from pediatric to adult health care: a qualitative study of young Australian adults. Disabil Rehabil 2004;26:223-34

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16

Eiser С Effects of chronic illness on children and their families. Adv Psychiatr Treat 1997; 3:204-10

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16

Kralik D, Visentin K, van Loon A. Transition: a literature review. J Adv Nurs 2006; 55:320-9

Cowlard J. Cystic fibrosis: transition from paediatric to adult care. Nursing Standard 2003; 18(4):39-4

Viner R. Transition from paediatric to adult care. Bridging the gaps or passing the buck. Arch Dis Child 1999; 81:271-5

Kralik D, Visentin K, van Loon A. Transition: a literature review. J Adv Nurs 2006; 55:320-9

Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

Own SJ, Bell SC. Transition of adolescents with cystic fibrosis from paediatric to adult care. Clin Respir J 2011;5:64-75

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16

Conway SP Transition from paediatric to adult-orientated care for adolescents with cystic fibrosis. Disabil Rehabil 1998;20:209-16